Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension	cardiovascular disorder, hypertensive disorder, resistant hypertension, vascular disorder	Not yet recruiting	Phase 2	2026-09-22		NCT07833098
VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population	cardiovascular disorder, hypertensive disorder, vascular disorder	Recruiting	Phase 1	2025-11-28		NCT07254481
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors	Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, cancer, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, rectal disorder, skin disorder	Recruiting	Phase 1 / Phase 2	2025-02-11		NCT06819215